Aviir Announces $30M Financial Investment in Cardiac Risk Assessment and Molecular Testing Services

Aviir, Inc., a biotechnology company specializing in cardiac disease assessment, announced that it entered into an agreement with multiple investors to raise up to $30 million in the company’s latest financing round. The financing includes an initial investment of $10 million and future investments of up to $20 million upon achieving certain milestones. The proceeds will be used to fund commercialization of TruRisk(TM), Aviir’s proprietary cardiac risk assessment technology, and additional molecular testing services provided through Aviir Heart Laboratories, based in Irvine, California.

Aviir CEO Dr. Douglas Harrington noted that ”While treatment has improved greatly, detection and prevention lags behind. Heart disease is still the number one killer in the world. Every year in the United States, 5 times more women die from heart attacks than from breast cancer. We aim to change these startling statistics by determining an individual’s risk of experiencing future cardiac events through our groundbreaking risk assessments, enabling them to take preventive action before it is too late. With this substantial financing, we look forward to saving even more lives through our laboratory and disease management services.”

For the full press release, click HERE.

 

This entry was posted in In The News. Bookmark the permalink.

Comments are closed.